Buy Pharmasset (VRUS) on Ambitious Phase 3 Program for '7977 - Baird

Baird said it continues to recommend the purchase of Pharmasset (NASDAQ: VRUS) following the start of ambitious Phase 3 program for '7977, which they say is the latest positive signal in front of AASLD updates.

The analyst commented, "VRUS's program stretches current thinking in the space and suggests a competitive two-drug, interferon-free regimen could be on the market ~H1-14. It also again signals that AASLD conference updates this weekend should make investors happy. We expect thinking will increasingly shift from drugs to regimens in HCV and remain with high conviction that VRUS is setting the (high) bar>"

The firm reiterated their Outperform rating and $88 price target.

For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.

Shares of Pharmasset are up 7 percent today to $75.49.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'
• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral